tradmap

LXEO Earnings Lexeo Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$36 -$18 $0 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $327000 $654000 2022 2023 2024 2025
Revenue
Net income (annual)
-$100M -$50M $0 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$32 -$16 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$33M -$16M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-37% -12% 12% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–16 of 16
Q2 20262026-06-30-0.552026-08-1210-Q
Q1 20262026-03-31-0.252026-05-1110-Q
FY 20252025-12-31-1.862026-03-3010-K
Q3 20252025-09-30-1.722025-11-0510-Q
Q2 20262025-06-30-1.532026-08-1210-Q
Q1 20262025-03-31-0.992026-05-1110-Q
FY 20252024-12-31-3.092026-03-3010-K
Q3 20252024-09-30-2.312025-11-0510-Q
Q2 20252024-06-30-1.412025-08-1410-Q
Q1 20252024-03-31-0.772025-05-1210-Q
FY 20242023-12-31-12.402025-03-2410-K
Q3 20242023-09-30-32.242024-11-1310-Q
Q2 20242023-06-30-19.872024-08-1210-Q
Q1 20242023-03-31-11.582024-05-0910-Q
FY 20232022-12-31-36.362024-03-1110-K
Q3 20232022-09-30-27.502023-12-1110-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.